Facio BioTherapies

FSHD Global Research Foundation has a commercialisation partner, Facio BioTherapies to enable pathways from benchtop to bedside for funded research and other promising FSHD focussed science.

Facio BioTherapies is an Australian biotechnology company that was founded with the specific goal of identifying novel therapies for Facioscapulohumeral Dystrophy (FSHD).  We collaborate with leading research centres worldwide to target both FSHD1 and FSHD2 genetic subtypes, striving to develop groundbreaking biotech solutions that improve patients’ lives.

FSHD Global Research Foundation has representation on the Facio BioTherapies’ Board, along with experienced scientists, researchers and business executives who are passionate about biotechnology. We are progressing research and development of “best-in-class” therapeutics for FSHD.